Drug Profile
ARP 1536
Alternative Names: ARP-1536Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Aerpio Pharmaceuticals
- Developer Aadi Bioscience
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Receptor-like protein tyrosine phosphatase inhibitors; TIE receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Kidney disorders
- No development reported Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Intravitreous, Injection)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Parenteral)
- 26 Aug 2021 Aadi Bioscience has merged with Aerpio Pharmaceuticals to form Aadi Bioscience